About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
The Jerusalem Post reports on a technology, developed by Prof. Ido Amit and team, that reveals the inner functions of cells. This could lead to new cancer immunotherapies.
August 14, 2020
Covering the recent breakthrough by Dr. Ravid Straussman, New Scientist says that the “first comprehensive survey of the microorganisms that live inside tumours has found that bacteria reside in those from many different cancer types.”
May 28, 2020
May is Skin Cancer Awareness Month, and Israel21C reports on research advances – including by Prof. Yardena Samuels.
May 14, 2020
The Economic Times reports that one of the reasons glioblastomas are so hard to treat is that the cancer cells come in four types – and can move between the types. The research was conducted by Weizmann and an international team.
September 27, 2019
Israeli and U.S. researchers found that glioblastoma brain cancer cells come in four states and can transition from one state to another, the Weizmann Institute of Science (WIS) in central Israel reported on Monday.
September 23, 2019
The Times of Israel reports on new research by Prof. Yardena Samuels’s lab that could lead to new, more personalized treatments for cancer.
September 13, 2019
The Jerusalem Post reports on a company established by a Weizmann Institute alum, Nir Erez, who left a job in big pharma to find a way to help cancer sufferers. His firm, Trial-In Pharma, connects patients to 20,000 clinical trials and compassionate use treatments worldwide.
March 24, 2019
Israel21C reports on a new Weizmann technique that profiles the genetic makeup of cancerous cells. The discovery could help blood cancer patients receive earlier and more precise treatment and prevent relapse.
January 02, 2019
Horizon, the EU Research & Innovation Magazine, reports on a breakthrough by Dr. Liran Shlush in diagnosing AML, a form of leukemia that is typically diagnosed at a late stage. Shlush has found a way to predict AML long before symptoms appear.
December 04, 2018
©2020 American Committee for the Weizmann Institute of Science